$1.43
-3.5%Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. in September 2025. Lite Strategy, Inc. was incorporated in 2000 and is based in San Diego, California.
Last Annual Value
17.09M
3-Year CAGR
-47%
5-Year CAGR
-29%
10-Year CAGR
-16%
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
![]() Lite Strategy, Inc. NASDAQ:LITS | 17.09M | -41.6% | -28.9% | N/A | |
![]() Relmada Therapeutics, Inc. NASDAQ:RLMD | 59.10M | -17.1% | -14.0% | 23.4% | |
![]() TScan Therapeutics, Inc. NASDAQ:TCRX | 143.27M | 7.8% | 19.5% | N/A | |
![]() Acrivon Therapeutics, Inc. Common Stock NASDAQ:ACRV | 82.76M | 7.5% | 38.6% | N/A | |
![]() Clene Inc. NASDAQ:CLNN | 23.24M | -17.3% | -14.3% | N/A | |
![]() Prelude Therapeutics Incorporated NASDAQ:PRLD | 115.00M | -4.6% | 0.2% | N/A | |
![]() Unicycive Therapeutics, Inc. NASDAQ:UNCY | 28.95M | 10.5% | 26.4% | N/A | |
![]() Vaxart, Inc. NASDAQ:VXRT | 219.18M | 36.5% | 54.5% | 19.7% | |
![]() Adicet Bio, Inc. NASDAQ:ACET | 115.73M | -8.7% | 10.2% | 220.9% | |
![]() PMV Pharmaceuticals, Inc. NASDAQ:PMVP | 86.21M | 3.0% | 8.6% | N/A | |
![]() Werewolf Therapeutics, Inc. NASDAQ:HOWL | 59.04M | 0.2% | 3.3% | N/A |
Continue your LITS research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.